Physician profile
Eun Young Ko
NPI 1700659570
$1,742.69
in general payments reported to CMS, 2019-2025
19 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $25.00 · 2024: $1,215 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $542.05 | 2024 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $163.80 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $159.56 | 2024-2025 | |
| Abbvie INC. | $155.43 | 2023-2025 | |
| Dexcom, INC. | $136.12 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Exact Sciences Corporation | $104.12 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $85.15 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $56.08 | 2024 | Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $54.39 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $46.34 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $39.42 | 2024 | Mounjaro, Zepbound |
| Scilex Pharmaceuticals INC. | $33.64 | 2024 | |
| Radius Health, INC. | $32.22 | 2024 | Tymlos |
| Corcept Therapeutics | $31.26 | 2025 | Korlym |
| Astellas Pharma US INC | $26.91 | 2025 | Veozah |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $21.88 | 2024 | Edarbyclor |
| Averitas Pharma INC. | $21.56 | 2024 | Qutenza |
| Sumitomo Pharma America, INC. | $17.45 | 2025 | Gemtesa |
| Shield Therapeutics INC | $15.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eun Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.